Show simple item record

dc.creatorPetrović, Stanislava
dc.creatorBogavac-Stanojević, Nataša
dc.creatorLakić, Dragana
dc.creatorPeco-Antić, Amira
dc.creatorVulicević, Irena
dc.creatorIvanišević, Ivana
dc.creatorKotur-Stevuljević, Jelena
dc.creatorJelić-Ivanović, Zorana
dc.date.accessioned2019-09-02T11:48:42Z
dc.date.available2019-09-02T11:48:42Z
dc.date.issued2015
dc.identifier.issn1330-0962
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/2467
dc.description.abstractIntroduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.en
dc.publisherCroatian Soc Medical Biochemists, Zagreb
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175035/RS//
dc.rightsopenAccess
dc.sourceBiochemia Medica
dc.subjectacute kidney injuryen
dc.subjectcardiac surgeryen
dc.subjectchildrenen
dc.subjectbiomarkersen
dc.subjectcost effectiveness analysisen
dc.titleCost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgeryen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractБогавац-Станојевић, Наташа; Јелић-Ивановић, Зорана; Лакић, Драгана; Котур-Стевуљевић, Јелена; Иванишевић, Ивана; Вулицевић, Ирена; Пецо-Aнтић, Aмира; Петровић, Станислава;
dc.citation.volume25
dc.citation.issue2
dc.citation.spage262
dc.citation.epage271
dc.citation.other25(2): 262-271
dc.citation.rankM21
dc.identifier.wos000356588100014
dc.identifier.doi10.11613/BM.2015.027
dc.identifier.pmid26110039
dc.identifier.scopus2-s2.0-84930421453
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/1145/2465.pdf
dc.identifier.rcubconv_3332
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record